Close

Sapien 3 transcatheter heart valve, breakthrough medical device from Edwards Lifesciences

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Growing Adoption of Robotic-Assisted Keyhole Surgery

In recent years, the field of surgery has gone...

From Patients to Platforms – Evolution of Smart Care Loop

In an era in which healthcare happens to be...

Unlocking AI Healthcare Mobility for Smarter Care 2025

Unlocking the Power of AI in Healthcare Management to...
What’s described as a breakthrough heart valve tested by doctors at Christ Hospital has been approved by the U.S. Food and Drug Administration.
The Mount Auburn-based hospital was one of the few research sites in the nation to participate in the clinical trial of the Sapien 3 transcatheter heart valve, which the FDA approved for use in patients who would be at high risk of undergoing traditional open-heart surgery.
The valve is used in a procedure known as transcatheter aortic valve replacement, or TAVR. The procedure allows a diseased heart valve to be replaced with a bioengineered valve without open-heart surgery.
The Sapien 3 valve, developed by Edwards Lifesciences of Irvine, Calif., was designed to provide a simpler procedure with fewer complications and faster recovery.
The FDA said it based approval of the Sapien 3 on a clinical study involving 583 patients, including those at Christ Hospital, with a narrowing in the heart’s aortic valve.
So-called aortic valve stenosis obstructs blood flow from the heart into the aorta and onto the rest of the body, which can lead to serious problems such as fainting, chest pain, heart failure, irregular heart rhythms or cardiac arrest, according to the FDA.
The trial at Christ Hospital was performed by a team led by Dr. Dean Kereiakes, medical director of the Heart and Vascular Center and the Carl and Edyth Lindner Center for Research and Education.
“Patients obviously prefer the less invasive surgery,” Kereiakes said. “We are both fortunate and proud to offer leading-edge technologies like the Sapien 3 transcatheter heart valve to patients in our community as part of a clinical trial years before they could otherwise get these treatments.”

Latest stories

Related stories

The Growing Adoption of Robotic-Assisted Keyhole Surgery

In recent years, the field of surgery has gone...

From Patients to Platforms – Evolution of Smart Care Loop

In an era in which healthcare happens to be...

Unlocking AI Healthcare Mobility for Smarter Care 2025

Unlocking the Power of AI in Healthcare Management to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back